91192-32-4

Usage

Uses

Used in Pharmaceutical Research:
2-HYDROXY-6-METHOXYQUINOXALINE is used as a research compound for its potential pharmacological properties, including its antiviral, antimicrobial, and anticancer activities. Its unique structure allows it to be a valuable tool in the development of new drugs and compounds with therapeutic applications.
Used in Organic Synthesis:
In the field of organic synthesis, 2-HYDROXY-6-METHOXYQUINOXALINE serves as a building block for the production of various pharmaceuticals and agrochemicals. Its versatile chemical structure enables the creation of a wide range of compounds with different applications.
Used in Antiviral Applications:
2-HYDROXY-6-METHOXYQUINOXALINE is used as an antiviral agent, potentially inhibiting the replication and spread of viruses, making it a candidate for the development of antiviral medications.
Used in Antimicrobial Applications:
2-HYDROXY-6-METHOXYQUINOXALINE is also utilized as an antimicrobial agent, targeting the growth and proliferation of bacteria and other microorganisms, which can be instrumental in the creation of new antibiotics and antimicrobial treatments.
Used in Anticancer Applications:
2-HYDROXY-6-METHOXYQUINOXALINE is employed as an anticancer agent, potentially interfering with the growth and progression of cancer cells, offering a new avenue for cancer treatment and research.
Used in Agrochemical Production:
In the agrochemical industry, 2-HYDROXY-6-METHOXYQUINOXALINE is used as a building block for the development of pesticides and other agricultural chemicals, contributing to crop protection and yield enhancement.

InChI:InChI=1/C9H8N2O2/c1-13-6-2-3-7-8(4-6)10-5-9(12)11-7/h2-5H,1H3,(H,11,12)

Upstream product

• 90417-61-1 6-Methoxy-4-oxy-1H-quinoxalin-2-one 
• 111697-40-6 1-hydroxy-6-methoxy-2(1H)-quinoxalinone 
• 111697-39-3 1-acetoxy-6-methoxy-2(1H)-quinoxalinone 
• 298-12-4 Glyoxilic acid 
• 102-51-2 4-methoxy-1,2-phenylenediamine 
• 924-44-7 glyoxylic acid ethyl ester 
• 4685-47-6 3,4-dimethylanisole 
• 39266-92-7 6-methoxyquinoxaline 1,4-dioxide 
• 64376-06-3 acetoacetic acid-(4-methoxy-2-nitro-anilide) 

Downstream Products

• 55687-11-1 6-methoxy-2-chloroquinoxaline 
• 1315336-89-0 6-methoxyquinoxalin-2-yl 4-methylbenzenesulfonate 
• 1315336-99-2 6-methoxy-2-(perfluorophenyl)quinoxaline 
• 55686-93-6 2-chloro-7-methoxyquinoxaline 
• 39267-04-4 2,3-dichloro-6-methoxyquinoxaline 

Relevant academic research and scientific papers

Electro-oxidative C-H alkylation of quinoxalin-2(1: H)-ones with organoboron compounds

Radical cleavage of C-B bonds to accomplish C-H functionalization is synthetically appealing but practically challenging. We report herein a mild electro-oxidative method for efficient C-H alkylation of quinoxalin-2(1H)-ones by means of radical addition reactions of alkyl boronic acids and esters and alkyl trifluoroborates to afford C-C coupled products. This journal is

Electro-oxidative C-H azolation of quinoxalin-2(1H)-ones

We have developed a practical, general protocol for direct C-H azolation reactions of quinoxalin-2(1H)-ones by electro-oxidative cross-coupling. These mild reactions proceed under metal-, oxidant-, and reagent-free conditions to provide synthetically useful azolated quinoxalin-2(1H)-ones. Furthermore, the reactions can be carried out with a pencil lead as an electrode and a 3 V battery as a power source, revealing the remarkable flexibility of this protocol.

Rapid alkenylation of quinoxalin-2(1H)-ones enabled by the sequential Mannich-type reaction and solar photocatalysis

Herein, a rapid alkenylation of quinoxalin-2(1H)-ones enabled by a combination of Mannich-type reaction and solar photocatalysis is demonstrated. A wide range of functional groups are compatible, affording the corresponding products in moderate-to-good yields. Control experiments illustrate that the in situ generated 1O2 plays a central role in this reaction. This green and efficient strategy provides a practical solution for the synthesis of potentially bioactive compounds that containing a 3,4-dihydroquinoxalin-2(1H)-one structure.

Electrochemical decarboxylative C3 alkylation of quinoxalin-2(1: H)-ones with N -hydroxyphthalimide esters

We have developed a protocol for electrochemical decarboxylative C3 alkylation of a wide range of quinoxalin-2(1H)-ones under metal- and additive-free conditions. N-Hydroxyphthalimide esters derived from chain, cyclic, primary, secondary, and tertiary carboxylic acids with a broad scope proved to be suitable substrates. This operationally simple protocol performed in an undivided cell under constant-current conditions is suitable for late-stage functionalization of quinoxalin-2(1H)-ones. The reactions can even be carried out with a 3 V battery as a power source, which demonstrates that organic electrosynthesis can be accomplished without the need for specialized equipment.

Construction of C(sp2)?C(sp3) Bond between Quinoxalin-2(1H)-ones and N-Hydroxyphthalimide Esters via Photocatalytic Decarboxylative Coupling

A novel visible-light-driven decarboxylative coupling of alkyl N-hydroxyphthalimide esters (NHP esters) with quinoxalin-2(1H)-ones has been developed. This C(sp2)?C(sp3) bond-forming transformation exhibits excellent substrate generality with respect to both the coupling partners. Of note, a series of 3-primary alkyl-substituted quinoxalin-2(1H)-ones that were difficult to synthesize by previous methods could be obtained in moderate to excellent yields. Additionally, the mild conditions, easy availability of substrates, wide functional group tolerance and operational simplicity make this protocol practical in the synthesis of 3-alkylated quinoxalin-2(1H)-ones.

Hepatitis C virus inhibitors

Hepatitis C virus inhibitors having the general formula (I) are disclosed. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.

Α 7 as intranuclear hydroxynicotinic acetylcholine receptor quinuclidines compd.

PROBLEM TO BE SOLVED: To provide ligands for the nicotinic α-7 receptor used for the treatment of various disorders of the central nervous system, especially affective and neurodegenerative disorders.SOLUTION: The disclosure provides compounds of the specified formula I, including their salts, and compositions and methods using the compounds.

BIARYL ACETAMIDE COMPOUNDS AND METHODS OF USE THEREOF

Biaryl acetamide compounds and compositions and their methods of use are provided for modulating the activity of class III receptor tyrosine kinases and for the treatment, prevention or amelioration of one or more symptoms of disease of disorder mediated by class III receptor tyrosine kinases.

QUINUCLIDINE COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS

The disclosure provides compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds are ligands for the nicotinic α7 receptor and may be useful for the treatment of various disorders of the central nervous system, especially affective and neurodegenerative disorders.

NIACIN RECEPTOR AGONISTS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT

Compounds of the formula (I): as well as pharmaceutically acceptable salts and solvates are disclosed. The compounds are useful for treating dyslipidemias, and in particular, reducing serum LDL, VLDL and triglycerides, and raising HDL levels. Pharmaceutic